Disc Medicine, Inc. (NASDAQ:IRON) Director William Richard White Sells 2,560 Shares

Disc Medicine, Inc. (NASDAQ:IRON) Director William Richard White sold 2,560 shares of Disc Medicine stock in a transaction on Thursday, April 11th. The shares were sold at an average price of $31.80, for a total value of $81,408.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Disc Medicine Stock Performance

Disc Medicine stock opened at $30.52 on Tuesday. The business’s 50-day simple moving average is $57.94 and its two-hundred day simple moving average is $55.86. The company has a market cap of $736.75 million, a PE ratio of -8.74 and a beta of 0.18. Disc Medicine, Inc. has a fifty-two week low of $21.70 and a fifty-two week high of $77.60.

Disc Medicine (NASDAQ:IRON) last posted its quarterly earnings results on Thursday, March 21st. The company reported ($0.97) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.22). As a group, analysts predict that Disc Medicine, Inc. will post -4.44 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on IRON. Morgan Stanley cut their price target on Disc Medicine from $75.00 to $40.00 and set an “equal weight” rating on the stock in a report on Tuesday, April 2nd. Wedbush restated an “outperform” rating and set a $43.00 target price (down from $84.00) on shares of Disc Medicine in a research note on Monday, April 1st. Raymond James restated an “outperform” rating and set a $40.00 target price (down from $75.00) on shares of Disc Medicine in a research note on Monday, April 1st. HC Wainwright restated a “buy” rating and set a $70.00 target price on shares of Disc Medicine in a research note on Monday, April 1st. Finally, Stifel Nicolaus boosted their target price on Disc Medicine from $71.00 to $73.00 and gave the stock a “buy” rating in a research note on Monday, April 8th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, Disc Medicine has a consensus rating of “Moderate Buy” and an average target price of $57.29.

Hedge Funds Weigh In On Disc Medicine

Several institutional investors and hedge funds have recently modified their holdings of the stock. PNC Financial Services Group Inc. lifted its holdings in shares of Disc Medicine by 149.4% in the 4th quarter. PNC Financial Services Group Inc. now owns 10,000 shares of the company’s stock valued at $578,000 after buying an additional 5,990 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Disc Medicine by 14.9% in the 4th quarter. Vanguard Group Inc. now owns 764,544 shares of the company’s stock valued at $44,160,000 after buying an additional 99,092 shares during the period. Wellington Management Group LLP lifted its holdings in shares of Disc Medicine by 224.6% in the 4th quarter. Wellington Management Group LLP now owns 177,726 shares of the company’s stock valued at $10,265,000 after buying an additional 122,981 shares during the period. Goldman Sachs Group Inc. lifted its holdings in shares of Disc Medicine by 127.3% in the 4th quarter. Goldman Sachs Group Inc. now owns 62,175 shares of the company’s stock valued at $3,591,000 after buying an additional 34,821 shares during the period. Finally, Virtu Financial LLC acquired a new position in shares of Disc Medicine in the 4th quarter valued at about $797,000. Institutional investors and hedge funds own 83.70% of the company’s stock.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.